Pharmacogenomics - it's not just pharmacogenetics

Bailey, David; Bondar, Alexander A.; Furness, L. Mike

doi:10.1016/s0958-1669(98)80136-5

Cited by 73 publications

(22 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Since its inception pharmacogenetics has been necessarily limited by the available technology to circumscribed, 'keyhole' views of an individual's genetic makeup. Inherited variations in drug metabolism are usually monogenic.…”

Section: Pharmacogenomics Versus Pharmacogeneticsmentioning

confidence: 99%

Pharmacogenomics and the challenge to privacy

2002

View full text Add to dashboard Cite

Section: Pharmacogenomics Versus Pharmacogeneticsmentioning

confidence: 99%

Pharmacogenomics and the challenge to privacy

2002

View full text Add to dashboard Cite

“…Where ‘pharmacogenetics’ refers to the study of drugs based on known allele-specific genetic variations responsible for metabolizing drugs among individuals, the term ‘pharmacogenomics’ refers to the identification and elucidation of genetic variations which will impact on the efficacy of drugs or offer different targets. Rather than being a radically new approach to medicine, pharmacogenomics essentially applies concepts about variations in drug metabolism to the rest of the genome [13, 14]. …”

Section: Definitionsmentioning

confidence: 99%

Ethical, Social and Legal Implications of Pharmacogenomics: A Critical Review

Møldrup¹

2001

Public Health Genomics

View full text Add to dashboard Cite

Objective: My aim was to examine the ethical, social and legal implications of pharmacogenomics. Method: I performed a critical review of the literature. The primary focal point is the bioethical principle discussed. The second outcome measure is the perspective of the discussion. Results: This review documents that the pharmacogenomics issues of concern are comparable to issues concerning other genetic developments in general. However, two main issues are particular to the case of pharmacogenomics. Firstly, this review reveals that society, industry, groups and individuals appreciate the prospect of pharmacogenomics very differently. Secondly, there is a lack of research into the post-marketing implications of pharmacogenomics. Conclusion: An extensive focus on the ethical, social and legal implications of pharmacogenomics, in terms of both pre- as well as post-marketing issues, is essential. Also, a multidisciplinary approach which includes individual and group opinions in an upfront manner in the research and development process is essential. Otherwise, there is a substantial risk that the positive prospects of pharmacogenomics will not survive due to fear and a lack of acceptance and understanding on the part of the general public.

show abstract

“…The search for potential targets among RNA motifs may benefit from pharmacogenomics approaches which elucidate the influence of genetic polymorphisms on drug disposition and effects [74,75]. The most common type of genetic variation is due to single-nucleotide polymorphisms (SNPs) which have been demonstrated being able to cause different secondary structure arrangements in two human mRNAs [76].…”

Section: Definition and Explorationmentioning

confidence: 99%

Rational Drug Design and High-Throughput Techniques for RNA Targets

Hermann

Westhof²

2000

CCHTS

View full text Add to dashboard Cite

RNA molecules are the only known molecules which possess the double property of being depository of genetic information, like DNA, and of displaying catalytic activities, like protein enzymes. RNA molecules intervene in all steps of gene expression and in many other biological activities. Like proteins, RNAs achieve those biological functions by adopting intricate three-dimensional folds and architectures. Further, as in protein sequences, RNA sequences contain signatures specific for threedimensional motifs which participate in recognition and binding. In regulatory pathways, RNA molecules exist in equilibria between transient structures differentially stabilized by effectors such as proteins or cofactors. Therefore, RNA molecules display their potential as drug targets on different levels, namely in three-dimensional folds, in structural equilibria and in RNA-protein interfaces. Several examples will be described together with the already available techniques for combinatorial synthesis and high-throughput screening of potential drug and target RNA molecules.

show abstract

Pharmacogenomics - it's not just pharmacogenetics

Cited by 73 publications

References 47 publications

Pharmacogenomics and the challenge to privacy

Pharmacogenomics and the challenge to privacy

Ethical, Social and Legal Implications of Pharmacogenomics: A Critical Review

Rational Drug Design and High-Throughput Techniques for RNA Targets

Contact Info

Product

Resources

About